TON 2016. vol. 24, N S ‘PERE BEAD@ ES JOURNAL OF KAOHSIUNG MEDIC: CE PRIDIS HB FAS BF (Bevaci zumab) 8 8S HSERBESRLZEEIL SROeM ft: AED BSE BBL OF Be (Pith: Avastin — (cT3N2M1a) (ll PY ce RL BS PIT AY BRSTIG > Fira BE ATE: ALLS lL A: ACTOR EAL + GE AIBevacizumabii HKOBEMBA BRR Tt ATEATILIK We > (LA BIE «ASR ELSE ZK Hi > FCC AB Se FL aA: ee eR He = FLIER)» BERR 1G AiO. BNE) 2.4% > (HATE ELT + MERGES FUR LRH « B]— AGMT A ELAR LS CARE izumal I BC Be SFL ado ° fz BL SBR AY Ae HER + AC TUITE 28 Be ON Swi was B+ Be SP OH Be i 78 HS BH Bete Bi8 ie Ae Fa is PEA SHE > ER BADR FRA He AT EA RAO 46ma: ERATE (HBR) © PRAISE + GEAR #8 (Bevaci zumab) 3a RS (ii Et Be FEM RE BEF > AE CSR: 15% » FEC aYAE.Z BRAY HHL. 2 HER LN 2. ALB RTL 3. BSRHLIE4. BE SESH BCN BARES. FH (el PORE Se Se a Fire. — fl A BS: CRS MR FTL A =e AT BCE RABN RSS S SSE 7. GEA Be Sh8. EPOREHS9. ZEJUIR AZ EACIAIAY HUREARSEY (NSAID) & » HEH BT BE S58 DCN GUA BB IAIE RAE ANCA TBA 7 BE ee MB (Bevacizumab) 8888 OFA FARA E BE id PRL Bz Ws CE FL BAHT HA FR A EMRE SB SET] BEARS» / BAL BS BG RRR SE ° METRE > aks SERS RST TART sae > ABT AAL RA A ORL. » ESR FRM 24 EFL A Pa RES FARA BE 2ORLPRAPIGME + HBSS Pay RFE AHL ORAL > 1h PRIS AS Ey BR A Db BE © FRR AS et PRA ELIALIE BE SCPE Sit THERE Ve A Ball RIE SR eS RE. PIM + WA BE DEF SOREN * Ti HO A BA EY TSS ERS eA Bh EE i BSE OGG SAB RBA ES PERI ARLE > FA HED Beta Rak eA > AE wrathSEM: 1 Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren k Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. N Engl J Med 2004; 350:2335- 42 2.Han ES, Monk BJ. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 2007;105:3-6. 3.Badgwell BD, Camp ER, Feig B, Wolff RA, Eng C, Ellis LM, Cormier IN. Management of bevacizumab- associated bowel perforation: a case series and review of the literature. Ann Oncol 2008;19:577-82. 4.Hedrick E, Kozloff M, Hainsworth J, Badarinath $, Cohn A, Flynn P, Dong W, Suzuki S, Sarkar S, Sugrue M, Grothey A, and the BRITE Study 48 S ‘EEBEGO BE JOURNAL OF KACHSIUNG MEDICAL ASSOCIATION 2016. vol. 24, No.1 Investigators. Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE) [meeting abstracts. J Clin Oncol 2006;24(188) p. Abstract 3536. 5.Sugrue M, Kozloff M, Hainsworth J, Badarinath $, Cohn A, Dong W, Suzuki S, Sarkar $, Grothey A, and the BRITE Study Investigators lynn P, Steis R, . Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. J Clin Oncol 2006;18(Suppl.):(abstr 3535) 6.Saif MW, Mehra R. Incidence and management of bevacizumab-related toxicities in colorectal cancer. Expert Opin Drug Saf 2006;5:553-66. 7.Asmis TR, Chung KY, Teitcher JB, Kelsen DP, Shah MA intestinalis: a variant of bevacizumab Pneumatosis related perforation possibly associated with chemotherapy related GI toxicity. Invest New Drugs 2008;26:95-6,